This theory is supported by a recent study showing that inhibition of IL-1β starting at an extended time-point after reperfusion results in improved systolic function in an ischemia-reperfusion rat model, with already established cardiac dilation and dysfunction [52]. The gene discussed is IL1B; the disease is ischemia.